Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda, Ascentage Pharma sign option agreement for olverembatinib
This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the
This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the
The alliance will harness the potential of traditional medical compounds in the fight against bacterial infections. Quadram’s TraDIS-Xpress platform will be utilised to innovate antibacterial treatments by studying
These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation
This partnership will focus on developing a translational medicine ecosystem and launching innovative research initiatives in Abu Dhabi. The second MoU outlines plans to design and develop a
This development follows the clearance for an investigational new drug (IND) application by the FDA for the asset last month. The fast track status is expected to expedite
A decision on the approval under the Prescription Drug User Fee Act (PDUFA) is anticipated on 25 January 2025. LEQEMBI is intended to treat AD patients having mild
The investment is managed by the funds of Permira and is expected to close by the fourth quarter of 2024, subject to necessary approvals and conditions. The companies
Currently, AGMB-447 is being assessed in an ongoing Phase I clinical trial as a potential treatment for IPF. The single-centre, integrated trial aims to evaluate the safety, tolerability,
Fast Track process of the FDA is intended to accelerate the development and review of drugs that address serious conditions and fill unmet medical needs. Lunresertib along with
The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle